The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis

Hosseinkhani, Negar; Asadzadeh, Zahra; Brunetti, Oronzo; Silvestris, Nicola; Baradaran, Behzad

doi:10.3389/fonc.2021.722833

Cited by 12 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glioma-initiating cells (GICs) showing a glioma stem cell (GSC) phenotype [ 22 , 23 ] colonize tumor areas with elevated hypoxia and “palisading necrosis” [ 24 , 25 ]. Residual infiltrating GICs result in less sensitivity to therapies and consequently GBM recurrence [ 26 , 27 ]. Moreover, resident nontumor cells, including infiltrating lymphocytes and glioma-associated microglia/macrophages constituting the tumor stroma [ 28 , 29 ], are responsible, in part, for the altered malignancy of GBM, as this cell population supports angiogenesis, growth, and invasiveness.…”

Section: Introductionmentioning

confidence: 99%

ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma

Gravina

Colapietro

Mancini

et al. 2022

Cancers

View full text Add to dashboard Cite

Cell proliferation requires the orchestrated actions of a myriad of proteins regulating DNA replication, DNA repair and damage tolerance, and cell cycle. Proliferating cell nuclear antigen (PCNA) is a master regulator which interacts with multiple proteins functioning in these processes, and this makes PCNA an attractive target in anticancer therapies. Here, we show that a cell-penetrating peptide containing the AlkB homolog 2 PCNA-interacting motif (APIM), ATX-101, has antitumor activity in a panel of human glioblastoma multiforme (GBM) cell lines and patient-derived glioma-initiating cells (GICs). Their sensitivity to ATX-101 was not related to cellular levels of PCNA, or p53, PTEN, or MGMT status. However, ATX-101 reduced Akt/mTOR and DNA-PKcs signaling, and a correlation between high Akt activation and sensitivity for ATX-101 was found. ATX-101 increased the levels of γH2AX, DNA fragmentation, and apoptosis when combined with radiotherapy (RT). In line with the in vitro results, ATX-101 strongly reduced tumor growth in two subcutaneous xenografts and two orthotopic GBM models, both as a single agent and in combination with RT. The ability of ATX-101 to sensitize cells to RT is promising for further development of this compound for use in GBM.

show abstract

Section: Introductionmentioning

confidence: 99%

ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma

Gravina

Colapietro

Mancini

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…We also detected differences in the alternative splicing of prominin 1 mRNA ( Prom1 ) (also known as CD133) and chose to follow up on Prom1 as it is associated with glioma recurrence and cancer therapy resistance (Abdoli Shadbad et al, 2021). We found that this gene undergoes three alternative splicing events that are differentially present in the culture configurations: one in the extracellular domain (EC), and two in the intracellular region (IC1 and IC2) (Figure S5b,c).…”

Section: Resultsmentioning

confidence: 99%

Cooperative and competitive regulation of the astrocytic transcriptome by neurons and endothelial cells: Impact on astrocyte maturation

Martínez-Lozada

Farmer

Schober

et al. 2023

Journal of Neurochemistry

View full text Add to dashboard Cite

Astrocytes have essential roles in central nervous system (CNS) health and disease. During development, immature astrocytes show complex interactions with neurons, endothelial cells, and other glial cell types. Our work and that of others have shown that these interactions are important for astrocytic maturation. However, whether and how these cells work together to control this process remains poorly understood. Here, we test the hypothesis that cooperative interactions of astrocytes with neurons and endothelial cells promote astrocytic maturation. Astrocytes were cultured alone, with neurons, endothelial cells, or a combination of both. This was followed by astrocyte sorting, RNA sequencing, and bioinformatic analysis to detect transcriptional changes. Across culture configurations, 7302 genes were differentially expressed by 4 or more fold and organized into 8 groups that demonstrate cooperative and antagonist effects of neurons and endothelia on astrocytes. We also discovered that neurons and endothelial cells caused splicing of 200 and 781 mRNAs, respectively. Changes in gene expression were validated using quantitative PCR, western blot (WB), and immunofluorescence analysis. We found that the transcriptomic data from the three‐culture configurations correlated with protein expression of three representative targets (FAM107A, GAT3, and GLT1) in vivo. Alternative splicing results also correlated with cortical tissue isoform representation of a target (Fibronectin 1) at different developmental stages. By comparing our results to published transcriptomes of immature and mature astrocytes, we found that neurons or endothelia shift the astrocytic transcriptome toward a mature state and that the presence of both cell types has a greater effect on maturation than either cell alone. These results increase our understanding of cellular interactions/pathways that contribute to astrocytic maturation. They also provide insight into how alterations to neurons and/or endothelial cells may alter astrocytes with implications for astrocytic changes in CNS disorders and diseases.image

show abstract

“…45 With a 10% cut-off, CD133 protein overexpression is associated with inferior PFS in patients with glioblastoma. 46…”

Section: Prognostication Factors-biomarkersmentioning

confidence: 99%

Disease-Based Prognostication: Neuro-Oncology

Waite,

Cioffi,

Malkin

et al. 2023

Semin Neurol

View full text Add to dashboard Cite

Primary malignant and non-malignant brain and other central nervous system (CNS) tumors, while relatively rare, are a disproportionate source of morbidity and mortality. Here we provide a brief overview of approaches to modeling important clinical outcomes, such as overall survival, that are critical for clinical care. Because there are a large number of histologically distinct types of primary malignant and non-malignant brain and other CNS tumors, this chapter will provide an overview of prognostication considerations on the most common primary non-malignant brain tumor, meningioma, and the most common primary malignant brain tumor, glioblastoma. In addition, information on nomograms and how they can be used as individualized prognostication tools by clinicians to counsel patients and their families regarding treatment, follow-up, and prognosis is described. The current state of nomograms for meningiomas and glioblastomas are also provided.

show abstract

The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis

Cited by 12 publications

References 33 publications

ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma

ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma

Cooperative and competitive regulation of the astrocytic transcriptome by neurons and endothelial cells: Impact on astrocyte maturation

Disease-Based Prognostication: Neuro-Oncology

Contact Info

Product

Resources

About